Two members of NCCN’s Global Policy team are presenting original research abstracts on National Cancer Control Plans and Tailoring Guidelines for Regional Realities as part of the three-day World Cancer Congress in Hong Kong.

A new artificial intelligence (AI) framework that combines ultrasound (US) with digital breast tomosynthesis (DBT) may improve breast-level risk classification by raising specificity while preserving sensitivity. 

For postmenopausal patients with ER+/HER2-negative early breast cancer and low Oncotype DX scores, findings from the TAILORx and RxPONDER trials support omitting adjuvant chemotherapy when cancer is node-negative or involves one to three lymph nodes. However, chemotherapy’s benefit remains uncertain for patients with high anatomic risk disease because prospective randomized evidence is limited. The RxFINE-Low (EA1242) trial evaluates whether chemotherapy adds benefit when patients receive endocrine therapy plus a CDK4/6 inhibitor to prevent recurrence. 

Human breath could help identify cancerous lung nodules, negating the need for invasive testing.

A joint team of researchers at Bar-Ilan University and the Weizmann Institute has used advanced computational design methods to enhance the ability of genetically engineered immune cells to recognize and attack cancer and viral targets.

Explore new St. Jude research finding how removing the immune response “brake” gene ZMYND8 led to better control of solid tumors and chronic viral infections.

A new study published in Myeloid Cells (MC) reports that AS01, a vaccine adjuvant system best known for its use in AS01-adjuvanted vaccines, can induce trained immunity in human monocytes and reduce tumor growth in selected mouse cancer models.